Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) EPS (Basic) (2021 - 2025)

Historic EPS (Basic) for InMed Pharmaceuticals (INM) over the last 5 years, with Q3 2025 value amounting to -$0.44.

  • InMed Pharmaceuticals' EPS (Basic) rose 8376.38% to -$0.44 in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.45, marking a year-over-year increase of 5278.18%. This contributed to the annual value of -$8.36 for FY2025, which is 5847.58% up from last year.
  • InMed Pharmaceuticals' EPS (Basic) amounted to -$0.44 in Q3 2025, which was up 8376.38% from -$1.83 recorded in Q2 2025.
  • InMed Pharmaceuticals' EPS (Basic)'s 5-year high stood at -$0.14 during Q2 2023, with a 5-year trough of -$15.24 in Q3 2023.
  • In the last 5 years, InMed Pharmaceuticals' EPS (Basic) had a median value of -$3.64 in 2024 and averaged -$4.44.
  • Its EPS (Basic) has fluctuated over the past 5 years, first soared by 9894.58% in 2023, then plummeted by 256238.74% in 2024.
  • InMed Pharmaceuticals' EPS (Basic) (Quarter) stood at -$7.73 in 2021, then skyrocketed by 88.23% to -$0.91 in 2022, then plummeted by 307.69% to -$3.71 in 2023, then increased by 1.89% to -$3.64 in 2024, then soared by 87.91% to -$0.44 in 2025.
  • Its EPS (Basic) stands at -$0.44 for Q3 2025, versus -$1.83 for Q2 2025 and -$1.94 for Q1 2025.